Data gathered: January 21
AI Stock Analysis - Crinetics Pharmaceuticals (CRNX)
Analysis generated July 24, 2024. Powered by Chat GPT.
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company specializes in developing oral nonpeptide small molecule drugs for hormone-dependent diseases. Crinetics operates at the forefront of a competitive and potentially lucrative market, which targets unmet medical needs in the endocrine segment.
Stock Alerts - Crinetics Pharmaceuticals (CRNX)
 |
Crinetics Pharmaceuticals | January 14 Price is down by -5.1% in the last 24h. |
|
Crinetics Pharmaceuticals | January 13 Price is down by -6.1% in the last 24h. |
|
Crinetics Pharmaceuticals | January 10 Price is down by -7.2% in the last 24h. |
|
Crinetics Pharmaceuticals | January 8 Insider Alert: Pizzuti Dana is selling shares |
Alternative Data for Crinetics Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 28 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 60 | Sign up | Sign up | Sign up |
| Patents | 49 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 1,131 | Sign up | Sign up | Sign up |
| Instagram Followers | 140 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 774 | Sign up | Sign up | Sign up |
| Twitter Followers | 948 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 87 | Sign up | Sign up | Sign up |
| Linkedin Employees | 374 | Sign up | Sign up | Sign up |
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors.
| Price | $38.82 |
| Target Price | Sign up |
| Volume | 880,460 |
| Market Cap | $3.46B |
| Year Range | $35.62 - $60.69 |
| Dividend Yield | 0% |
| Analyst Rating | 92% buy |
| Industry | Biotechnology |
In the news
 |
Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns “Buy” Rating from HC WainwrightJanuary 14 - ETF Daily News |
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10 - Finnhub |
|
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6 - GlobeNewswire |
|
|
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Buy” from AnalystsJanuary 2 - ETF Daily News |
 |
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market WeaknessJanuary 1 - SeekingAlpha |
 |
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)January 9 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 26M | -26M | -77M | -87M | 0.000 |
| Q2 '24 | 400,000 | 25M | -24M | -74M | -82M | -0.940 |
| Q1 '24 | 130,000 | 21M | -21M | -67M | -73M | -0.930 |
| Q4 '23 | 0 | 17M | -22M | -60M | -62M | -0.900 |
| Q3 '23 | 350,000 | 15M | -15M | -57M | -59M | -1.010 |
Insider Transactions View All
| Pizzuti Dana filed to sell 29,248 shares at $52.1. January 7 '25 |
| Struthers Richard Scott filed to sell 100,000 shares at $57.6. December 4 '24 |
| Knight Jeff E. filed to sell 51,653 shares at $56.5. November 26 '24 |
| Pizzuti Dana filed to sell 28,507 shares at $54.6. October 7 '24 |
| Wilson Marc filed to sell 111,092 shares at $51.1. September 30 '24 |
Similar companies
Read more about Crinetics Pharmaceuticals (CRNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Crinetics Pharmaceuticals?
The Market Cap of Crinetics Pharmaceuticals is $3.46B.
What is the current stock price of Crinetics Pharmaceuticals?
Currently, the price of one share of Crinetics Pharmaceuticals stock is $38.82.
How can I analyze the CRNX stock price chart for investment decisions?
The CRNX stock price chart above provides a comprehensive visual representation of Crinetics Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crinetics Pharmaceuticals shares. Our platform offers an up-to-date CRNX stock price chart, along with technical data analysis and alternative data insights.
Does CRNX offer dividends to its shareholders?
As of our latest update, Crinetics Pharmaceuticals (CRNX) does not offer dividends to its shareholders. Investors interested in Crinetics Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Crinetics Pharmaceuticals?
Some of the similar stocks of Crinetics Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.